Overview

IBP-9414 for the Prevention of Necrotizing Enterocolitis

Status:
Completed
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.
Phase:
Phase 2
Details
Lead Sponsor:
Infant Bacterial Therapeutics